Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $117 | $109 | $154 | $154 |
| Short-Term Investments | $337 | $360 | $362 | $429 |
| Receivables | $25 | $37 | $21 | $14 |
| Inventory | $28 | $18 | $5 | $0 |
| Other Curr. Assets | $23 | $8 | $6 | $6 |
| Total Curr. Assets | $530 | $532 | $549 | $603 |
| Property Plant & Equip (Net) | $2 | $2 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $20 | $63 | $90 | $120 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $22 | $64 | $92 | $122 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $552 | $596 | $641 | $725 |
| Liabilities | – | – | – | – |
| Payables | $14 | $17 | $10 | $12 |
| Short-Term Debt | $23 | $0 | $0 | $13 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $77 | $95 | $84 | $79 |
| Total Curr. Liab. | $114 | $113 | $95 | $104 |
| LT Debt | $322 | $1 | $1 | $333 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $324 | $330 | $0 |
| Total NC Liab. | $322 | $326 | $331 | $333 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $2 | $2 | $2 | $2 |
| Total Liabilities | $436 | $439 | $426 | $437 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,439 | -$1,378 | -$1,306 | -$1,221 |
| AOCI | $1 | $0 | $1 | $0 |
| Other Equity | $1,553 | $1,535 | $1,521 | $1,509 |
| Total Equity | $115 | $157 | $215 | $288 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $552 | $596 | $641 | $725 |
| Net Debt | $229 | -$107 | -$152 | $192 |